On Saturday MPA launched a major public awareness campaign to highlight World Melanoma Month.
Archive | Melanoma News
Relatlimab-nivolumab combination extends PFS in metastatic melanoma
A trial designed to evaluate the addition of relatlimab to nivolumab for untreated metastatic or unresectable melanoma met its primary endpoint of improved PFS, according to topline data released by the agent’s manufacturer.
Posted in Melanoma News, Health Professionals, Clinical Trials
Combination Treatment Improves Relapse-Free Survival Time
Patients with stage III melanoma receiving a combination treatment of dabrafenib (Tafinlar) and trametinib (Mekinist) achieved longer restricted mean survival times (RMST) compared to placebo, according to recent study results.1
Posted in Melanoma News, Health Professionals, Of Interest
Relatlimab/Nivolumab Improves PFS in Previously Untreated Metastatic or Unresectable Melanoma
The fixed-dose combination of relatlimab plus nivolumab (Opdivo) was found to improve progression-free survival (PFS) over nivolumab alone in patients with previously untreated metastatic or unresectable melanoma, meeting the primary end point of the phase 2/3 RELATIVITY-047 (CA224-047; NCT03470922) trial.1
Posted in Melanoma News, Health Professionals, Of Interest
